The use of fused PET/CT images for patient selection and radical radiotherapy target volume definition in patients with non-small cell lung cancer: results of a prospective study with mature survival data.

BACKGROUND AND PURPOSE This prospective study investigated the impact of radiotherapy (RT)-planning FDG-PET/CT on management of non-small cell lung cancer (NSCLC). MATERIALS AND METHODS Patients still eligible for radical RT after conventional staging underwent RT-planning PET/CT and, if disease was still treatable to 60 Gy, they entered our planning study, where visually-contoured tumour volumes derived with and without PET information were compared. If PET/CT detected advanced disease, palliative therapy was given. Overall survival (OS) for palliative and curative patients was compared. RESULTS Of 76 eligible patients, only 50 (66%) received radical chemoRT after PET/CT while 26 (34%) received palliative therapies because PET/CT detected advanced disease. Without PET, FDG-avid tumour would reside outside the planning target volume (PTV) in 36% of radical cases and in 25% <90% of the PTV would have received >95% prescribed dose. OS for all patients was 56.8% and 24.9% at 1 and 4 years, respectively. OS for patients given chemoRT was 77.5% and 35.6% at 1 and 4 years, respectively and was 32% for stage IIIA patients at 4 years. OS for patients treated palliatively was inferior (P<0.001); 16.3% and 4.1% at 1 and 4 years, respectively. CONCLUSIONS Planning PET/CT frequently changed management and was associated with excellent survival. Survival data from this study were presented in part at the 2011 World Lung Cancer Conference, Amsterdam and planning data at the 2010 Annual Scientific Meeting of the American Society for Therapeutic Radiology and Oncology, Chicago.

[1]  A R Feinstein,et al.  The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. , 1985, The New England journal of medicine.

[2]  Dirk De Ruysscher,et al.  PET scans in radiotherapy planning of lung cancer. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[3]  Philippe Lambin,et al.  Therapeutic implications of molecular imaging with PET in the combined modality treatment of lung cancer. , 2011, Cancer treatment reviews.

[4]  Tomio Inoue,et al.  Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006-2007. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[5]  M. M. Mac Manus,et al.  How can we tell if PET imaging for cancer is cost effective? , 2010, The Lancet. Oncology.

[6]  D. Schrag,et al.  Survival outcomes after radiation therapy for stage III non-small-cell lung cancer after adoption of computed tomography-based simulation. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Schneider-Kolsky,et al.  High rates of tumor growth and disease progression detected on serial pretreatment fluorodeoxyglucose‐positron emission tomography/computed tomography scans in radical radiotherapy candidates with nonsmall cell lung cancer , 2010, Cancer.

[8]  Use of PET/CT for staging and radiation therapy planning in patients with non-small cell lung cancer. , 2010 .

[9]  J. Matthews,et al.  Characteristics of 49 patients who survived for 5 years following radical radiation therapy for non-small cell lung cancer: the potential for cure. , 2000, International journal of radiation oncology, biology, physics.

[10]  R. Fisher,et al.  Measurement of lung tumor volumes using three-dimensional computer planning software. , 2002, International journal of radiation oncology, biology, physics.

[11]  Brian O'Sullivan,et al.  Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  K. Bujko,et al.  Impact of [18F]fluorodeoxyglucose PET-CT staging on treatment planning in radiotherapy incorporating elective nodal irradiation for non-small-cell lung cancer: a prospective study. , 2011, International journal of radiation oncology, biology, physics.

[13]  V. Valentini,et al.  18 F-FDG PET-CT during chemo-radiotherapy in patients with non-small cell lung cancer: the early metabolic response correlates with the delivered radiation dose , 2012, Radiation Oncology.

[14]  Robert Jeraj,et al.  PET scans in radiotherapy planning of lung cancer. , 2012, Lung cancer.

[15]  P. Marsden,et al.  Recommendations for the use of PET and PET-CT for radiotherapy planning in research projects. , 2012, The British journal of radiology.

[16]  David Binns,et al.  A prospective study to evaluate the impact of FDG-PET on CT-based radiotherapy treatment planning for oesophageal cancer. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[17]  Jan-Jakob Sonke,et al.  The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[18]  D. Owens,et al.  Test Performance of Positron Emission Tomography and Computed Tomography for Mediastinal Staging in Patients with NonSmall-Cell Lung Cancer , 2003, Annals of Internal Medicine.

[19]  M. Schneider-Kolsky,et al.  Interplanner variability in carrying out three‐dimensional conformal radiation therapy for non‐small‐cell lung cancer , 2008, Journal of medical imaging and radiation oncology.

[20]  D. Joseph,et al.  A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: final report of an Australian multi-centre trial. , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[21]  Shalini K Vinod,et al.  Diagnostic and staging impact of radiotherapy planning FDG-PET-CT in non-small-cell lung cancer. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[22]  K. Cease,et al.  The effect of radiation dose and chemotherapy on overall survival in 237 patients with Stage III non-small-cell lung cancer. , 2009, International journal of radiation oncology, biology, physics.

[23]  Hak Choy,et al.  A phase II comparative study of gross tumor volume definition with or without PET/CT fusion in dosimetric planning for non-small-cell lung cancer (NSCLC): primary analysis of Radiation Therapy Oncology Group (RTOG) 0515. , 2009, International journal of radiation oncology, biology, physics.

[24]  V Kalff,et al.  F‐18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma , 2001, Cancer.

[25]  D K Owens,et al.  Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. , 2001, JAMA.

[26]  R. Hicks,et al.  Where do we draw the line? Contouring tumors on positron emission tomography/computed tomography. , 2008, International journal of radiation oncology, biology, physics.

[27]  W. Curran,et al.  The Influence of Gender, Race, and Marital Status on Survival in Lung Cancer Patients: Analysis of Radiation Therapy Oncology Group Trials , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[28]  Rodney J Hicks,et al.  Reproducibility of "intelligent" contouring of gross tumor volume in non-small-cell lung cancer on PET/CT images using a standardized visual method. , 2007, International journal of radiation oncology, biology, physics.

[29]  U Nestle,et al.  Multi-centre calibration of an adaptive thresholding method for PET-based delineation of tumour volumes in radiotherapy planning of lung cancer , 2012, Nuklearmedizin.

[30]  Ursula Nestle,et al.  Practical integration of [18F]-FDG-PET and PET-CT in the planning of radiotherapy for non-small cell lung cancer (NSCLC): the technical basis, ICRU-target volumes, problems, perspectives. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[31]  R. Wahl,et al.  The promise and pitfalls of positron emission tomography and single-photon emission computed tomography molecular imaging-guided radiation therapy. , 2011, Seminars in radiation oncology.